Anixa Biosciences, Inc. (NASDAQ: ANIX) a US-based biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced on Monday that the company in collaboration with its partner Moffitt Cancer Center, has started treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

The study, a dose-escalation Phase one trial, is to assess safety and the maximum tolerated dose of follicle stimulating hormone receptor T-cells and will preliminarily evaluate its efficacy. It is being carried out at Moffitt Cancer Center and will include up to 48 participants.

Amit Kumar, PhD, Anixa Biosciences chairman and CEO, said, 'We are pleased that the first patient has been treated in our ovarian cancer CAR-T clinical study. This is truly an exciting time for Anixa, as we have now begun treating patients in our second clinical trial. With our CAR-T study, we hope to determine whether our unique targeting approach will work in solid tumours--a difficult challenge for traditional CAR-T therapies.'